SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
THE CLINICAL FEATURES, TREATMENTS, AND PROGNOSIS OF ADULT B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS IN TAIWAN
Huai-Hsuan Huang1, Bor-Sheng Ko1,2, Ming Yao1 and Hwei-Fang Tien1
(1) National Taiwan University Hospital, Taipei, Taiwan, (2) National Taiwan University Cancer Center,
Taipei, Taiwan
Background: The clinical features and prognosis of adult acute lymphoblastic leukemia (ALL)
patients are distinct from children. The application of tyrosine kinase inhibitors (TKI) improves
the prognosis of the patients with Philadelphia-chromosome-positive (Ph+) ALL. However, the
data from Taiwanese adult ALL patients are limited.
Aim: The aim of this study is to illustrate the clinical features, treatments, response, and
prognosis of adult ALL patients in Taiwan.
Methods: We conducted a single-center retrospective study including patients with newly
diagnosed B-ALL in National Taiwan University Hospital during 2013 and 2018. Patients
younger than 18 years were excluded. Minimal residual disease was detected by flow
cytometry in the bone marrow samples.
Results: We included 89 patients while 51 patients were diagnosed as B-ALL and 38 were
diagnosed as Ph+ ALL. The median age at diagnosis was 44.2 years and 49.8 years in B-ALL and
Ph+ ALL patients (p=0.486) respectively. The female-to-male ratio was 1.125 and 0.583 in B-ALL
patients and Ph+ ALL patients (p=0.134) respectively.
In the B-ALL patients, 45 (88.2%) patients received GRAALL 2003 or GRAALL 2005, one (2.0%)
patient received hyperCVAD, two (3.9%) patients received other treatments, and three (5.9%)
patients did not receive any chemotherapy. Five (9.8%) patients received rituximab, and 21
(41.2%) patients underwent hematopoietic stem cell transplantation (HSCT). After induction
chemotherapy, 38 (74.5%) achieved complete remission (CR) without detectable minimal
residual diseases (MRD), 7 (13.7%) achieved CR with MRD, one (2.0%) had partial response
(PR), two patients (3.9%) had refractory disease, and three patients died before hemogram
recovery. The median follow-up duration was 32.4 months with a median overall survival
(mOS) of 38.47 months. The relapse rate was 45.1%, and two patients (3.9%) had relapse at
the central nervous system (CNS). Patients younger than 40 years had better OS than older
(mOS, not reached vs 32.3 months; p=0.0210). Patients with detected MRD after HSCT had
shorter OS compared with those without MRD (mOS, 28.37 months vs 50.27 months;
p=0.0128).
In the Ph+ ALL patients, 22 (57.9%) patients had P190, 16 (42.1%) had P210, and 19 (50.0%)
patients had additional cytogenetic abnormalities. Twenty-three patients (62.2%) received
dasatinib and 14 (37.8%) patients received imatinib as the first TKI. Seven (18.4%) patients
received rituximab and 24 (63.2%) patients underwent HSCT. After induction treatments, 13
(34.2%) patients had CR without MRD, 23 (60.5%) patients had CR with MRD, and two (5.3%)
patients had refractory diseases. The median follow-up duration was 35.3 months and mOS
was not reached. Fifteen (39.5%) patient experience relapse, including 7 (18.4%) with CNS
relapse. Patients younger than 40 years had better OS than older (both mOS were not
reached; p=0.0351). The type of TKI did not influence OS in patients with P190, but patients
receiving dasatinib had better OS than those receiving imatinib (mOS, not reached vs 15.67
months; p=0.0164) in the patients with P210.
POSTER 34